Reta 60

Retatrutide is a synthetic 39-amino-acid peptide incorporating a fatty diacid acylation modification, engineered as a triple agonist that engages the GLP-1, GIP, and glucagon receptors concurrently. It has been investigated extensively in metabolic and endocrine peptide pharmacology research. The 60 mg presentation is intended for qualified research environments conducting extended, repeated, or high-volume laboratory protocols requiring a larger defined quantity of Retatrutide for controlled investigations into receptor pharmacology, metabolic signaling, energy homeostasis, and related preclinical research.

Key Features

• 60 mg research-grade Retatrutide
• Synthetic triple-receptor agonist peptide (LY3437943)
• Engineered fatty-acid acylation for extended systemic exposure in research models
• Relevant to metabolic and endocrine signaling research
• Suitable for receptor-binding and pathway-response studies
• Intended for controlled in-vitro and preclinical research
• Appropriate for peptide characterization and analytical workflows
• Batch-level analytical documentation may be provided for applicable lots

Research Focus

Retatrutide has been investigated in experimental models for its concurrent activity at the GLP-1, GIP, and glucagon receptors. Research has examined its influence on insulin secretion, glucose tolerance, and energy expenditure, providing a basis for continued investigation into coordinated multi-receptor signaling. Additional laboratory research has explored Retatrutide in relation to body-composition biochemical patterns and cellular response behavior under controlled experimental conditions. Much of the available mechanistic evidence comes from animal and cellular research models, with no published trial evaluating vial sizes at this quantity as a single dosing unit.

Important Notice

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary use, self-administration, consumption, weight management, diagnosis, treatment, or prevention of disease. This research material should be handled only by appropriately qualified personnel in accordance with applicable laboratory protocols, analytical requirements, and regulations.